Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases. The company is advancing anti-cancer therapies through multiple Phase 2 clinical trials in different cancers by targeting the enzyme telomerase and with a conpound designed to penetrate the blood-brain barrier. The four Phase 2 trials end in Q4 of 2012 results shouuld be in Dec 2012. The company is developing cell therapies from differentiated human embryonic stem cells for a range of indications, with the first product in a Phase 1 clinical trial for spinal cord injury. Four patients are now in the trial. For more infor visit www.geron.com .
On this blog I will be stating news that may move the stock up or down. Will be stating my trades. Showing , hopefully how I make money while waiting for the big price move up to $100 a share. A dream, maybe. This stock could do it.
No comments:
Post a Comment